Delays, cancellations, overbooking, misconnections and even diversions - every year, millions of travellers are affected by flight disruptions. In this scenario, a truly distinctive Italian company is leading the way globally in the management of irregular operations. Serving over 100 airlines and ground handling agents Value Group offers real solutions to travellers all over the world: as a trusted leader in IROPS management the company positions itself as an all-in-one partner, providing 360°...
Gradiant, a global leader in advanced water and wastewater solutions, today announced advancements in its ForeverGone PFAS destruction platform, establishing it as one of the most cost-effective and sustainable solutions for eliminating “forever chemicals” in industrial wastewater. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250929038872/en/Gradiant has announced advancements in its ForeverGone PFAS destruction platform and the c...
BECO Capital announces the close of $370 million across two new funds, expanding BECO’s ability to back founders from Pre-Seed to IPO, with a continued focus on the UAE and Saudi Arabia. The raise includes $120 million for BECO Fund IV, the firm’s fourth early-stage fund, and a $250 million Growth Fund. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250928385582/en/BECO Capital’s General Partnership team from left to right: Yousef H...
ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, today announced that Solaris SE, Europe’s leading embedded finance platform, has selected ACI Connetic to consolidate all SEPA instant payments onto ACI Connetic, ACI’s leading-edge technology, cloud-native payments platform. ACI Connetic is the industry’s only unified solution that seamlessly integrates account-to-account (A2A) payments, card processing, and AI-powered fraud prevention within a single, modular ...
Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion. The transaction has been unanimously approved by the Bo...
Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,” said Anna Sumeray, CEO of Virometix. “This fully synthetic, serotype-independent vaccine candidate is designe...